Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 1;37(2):150-157.
doi: 10.1097/CCO.0000000000001125. Epub 2025 Jan 16.

Cancer-associated thrombosis: what is new?

Isabelle Mahé  1 , Samuel Benarroch, Sadji Djennaoui, Rabiaa Hakem, Abdallah Ghorbel, Hélène Helfer, Jean Chidiac
Affiliations
Review

Cancer-associated thrombosis: what is new?

Isabelle Mahé et al. Curr Opin Oncol. .

Abstract

Purpose of review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.

Recent findings: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer.

Summary: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.

PubMed Disclaimer

References

    1. Crobach MJT, Anijs RJS, Braekkan SK, et al. Survival after cancer-related venous thrombosis: the Scandinavian thrombosis and cancer study. Blood Adv 2023; 7:4072–4079.
    1. Ording AG, Skjøth F, Søgaard M, et al. Increasing incidence and declining mortality after cancer-associated venous thromboembolism: a nationwide cohort study. Am J Med 2021; 134:868–876.
    1. Bertoletti L, Madridano O, Jiménez D, et al. Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC Cardio Oncol 2023; 5:758–772.
    1. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285–291.
    1. Sevestre M-A, Gaboreau Y, Douriez E, et al. Care pathways for patients with cancer associated thrombosis: from diagnosis to long-term follow-up. Arch Cardiovasc Dis 2024; 117:6–15.